EU Medicines Network Strategy Draft Consultation

The European Medicines Agency (EMA), along with the Heads of Medicines Agencies (HMA), has launched a draft of their joint EU network strategy aimed at the year 2028. This initiative is available for an eight-week public consultation period, welcoming feedback from the community. This update serves as a comprehensive review of the existing strategies.

The central theme encapsulated in the updated strategy is the notion of change—characterized by its rapid nature, unpredictability, yet filled with potential opportunities. This strategy is designed to direct the network as it navigates future challenges and possibilities.

The strategic focus areas established in the 2028 strategy include:

• Accessibility – Enhancing pathways for better access to medicines throughout the EU’s healthcare systems.
• Leveraging – Utilizing existing resources and data to optimize the evaluation processes.

The six focus areas have been meticulously selected to bolster the network’s essential task of evaluating medicines. This strategic direction aims to promote advancements in medication development while ensuring patient safety and efficacy, which remains a priority for the healthcare community.

Stakeholders are encouraged to provide their insights on the draft strategy until 30 November 2024. This can be done through an online questionnaire set up for this purpose. The EMA and HMA will continuously assess the progress made in each focus area laid out in the strategy.